173 related articles for article (PubMed ID: 30465789)
1. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1.
Yang Y; Zhang J; Wu T; Xu X; Cao G; Li H; Chen X
Life Sci; 2019 Jan; 216():200-206. PubMed ID: 30465789
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Ye P; Xing H; Lou F; Wang K; Pan Q; Zhou X; Gong L; Li D
Cancer Chemother Pharmacol; 2016 Mar; 77(3):613-21. PubMed ID: 26846508
[TBL] [Abstract][Full Text] [Related]
3. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
4. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells.
Jegal ME; Jung SY; Han YS; Kim YJ
BMB Rep; 2019 May; 52(5):330-335. PubMed ID: 30982500
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC.
Blukacz L; Nuciforo S; Fucile G; Trulsson F; Duthaler U; Wieland S; Heim MH
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38696353
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
[TBL] [Abstract][Full Text] [Related]
7. miR-381 Reverses Multidrug Resistance by Negative Regulation of the
Pu B; Yu X; Cao Y; Li Y; Tang L; Xia J
DNA Cell Biol; 2021 Dec; 40(12):1584-1596. PubMed ID: 34931867
[TBL] [Abstract][Full Text] [Related]
8. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
11. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
Yu M; Zou Q; Wu X; Han G; Tong X
Biomed Pharmacother; 2017 Nov; 95():1844-1852. PubMed ID: 28968929
[TBL] [Abstract][Full Text] [Related]
12. IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1).
Du J; He Y; Li P; Wu W; Chen Y; Ruan H
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1111-1119. PubMed ID: 29693201
[TBL] [Abstract][Full Text] [Related]
13. NRF2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells.
Xia X; Wang Q; Ye T; Liu Y; Liu D; Song S; Zheng C
Fundam Clin Pharmacol; 2020 Feb; 34(1):41-50. PubMed ID: 31420991
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
Zaja R; Caminada D; Loncar J; Fent K; Smital T
Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
[TBL] [Abstract][Full Text] [Related]
15. 1,25(OH)
Huang J; Yang G; Huang Y; Zhang S
Biochimie; 2018 Mar; 146():28-34. PubMed ID: 29158005
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin.
Fang S; Qiu J; Wu Z; Bai T; Guo W
Oncotarget; 2017 Jul; 8(30):49783-49795. PubMed ID: 28572537
[TBL] [Abstract][Full Text] [Related]
17. Reduced cytotoxicity in doxorubicin-exposed HepG2 cells pretreated with menthol due to upregulation of P-glycoprotein.
Nagai K; Fukuno S; Miura T; Uchino Y; Sehara N; Konishi H
Pharmazie; 2020 Oct; 75(10):510-511. PubMed ID: 33305727
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
19. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
[TBL] [Abstract][Full Text] [Related]
20. 1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).
Huang J; Yang G; Huang Y; Kong W; Zhang S
Mol Med Rep; 2016 Feb; 13(2):1373-80. PubMed ID: 26676829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
